Temasek-backed Homology Medicines priced its shares at $16 and raised $165m when it floated on the Nasdaq Global Select Market.

Homology Medicines, a US-based rare disease treatment developer backed by Temasek, the Singaporean state-owned investment firm, has raised $165.6m in its initial public offering and listed on the Nasdaq Global Select Market. The company, which had originally targeted $100m in proceeds, priced its shares at $16 each, offering a total of nine million shares to…

The rest of this content is only accessible to Global Government Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.